Air pollution inside Philly’s subway is much worse than on the streets
Three accused in 'Farmgate' Ramaphosa break-in appear in South African court
Equinor buys 9.8% stake in Orsted valued at $2.5 billion
Ex-Philippine President Duterte to run as mayor despite his drug killings legacy
Israeli soldiers kill Palestinian boy in West Bank confrontations, health ministry says
Pope Francis slams world's 'shameful inability' to stop Israel-Hamas war
Monster payrolls see 10-year Treasury yields top 4%
Wall Street futures down on rates rethink, geopolitical risks
Ravens claim wild overtime victory, Texans snatch last-second win and Jayden Daniels keeps rolling: NFL Week 5 Sunday review
Al Pacino reveals he nearly died of Covid-19 – and gives his thoughts on the afterlife
‘It was a massive thing’ to be England’s first Black football player, says Viv Anderson
(Reuters) -The U.S. Food and Drug Administration on Friday warned patients and doctors about dosing errors associated with compounded versions of Novo Nordisk's weight-loss and diabetes drugs.
The health regulator said it had received reports of adverse events, some requiring hospitalization, that may be related to overdoses due to patients incorrectly self-administering the compounded drug and healthcare providers miscalculating doses.
The FDA flagged the higher risk to patients from the use of compounded drugs, which may contain additional ingredients, and may contribute to potential medication errors. It urged healthcare providers and compounders to provide the appropriate syringe size and counsel patients on how to measure the dose.
Overdoses with these drugs could cause adverse effects including severe nausea, vomiting and low blood sugar levels.
The explosive demand has created a huge shortage and fueled a booming global market for cheaper versions, sometimes even counterfeits.
The FDA has also expressed serious concerns about the prevalence of fake versions of Novo's diabetes drug Ozempic and other drugs approved for weight loss, including Novo's Wegovy and Eli Lilly's Zepbound.
Semaglutide, the key ingredient in Wegovy and Ozempic, belongs to the GLP-1 class of drugs, which work by helping control blood sugar levels and triggering a feeling of fullness.
Novo's Wegovy is available as single-dose pre-filled pens that deliver a preset dose for once weekly dosing, while Ozempic is available as multiple-dose pre-filled pens for single-patient use, designed for once-weekly dosing.
(Reporting by Mariam Sunny in Bengaluru; Editing by Shinjini Ganguli and Sriraj Kalluvila)
